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Iron is a micronutrient important in energy homeostasis. Due to its oxidative 
capacity, it serves as the active site for many redox enzymes both as a component of iron 
sulfur clusters and heme, and iron-containing proteins are found in biochemical pathways 
important in energy utilization such as the citric acid cycle and the electron transport 
chain. The oxidative properties of iron can also be toxic since reduced iron is able to 
undergo Fenton chemistry to catalyze the formation of reactive oxygen species (ROS). At 
normal levels, ROS serves a signaling function important for a diverse array of processes, 
including cellular differentiation, metabolic adaptation, and innate immunity.  Excess 
ROS can produce oxidative stress that affects those pathways and can also oxidize lipids, 
proteins, and nucleic acids.  
Herein we explored the role of dietary iron in glucose metabolism both as it 
affects adenosine monophosphate-activated protein kinase (AMPK) and the circadian 
factor Rev-Erbα. In the study of both of these proteins, we found that moderate increases 
in dietary iron are able to create a shift in the oxidative potential of the cell as measured 
by increased levels of protein carbonylation, and decreased levels glutathione (GSH), and 
a decreased ratio of reduced to oxidized nicotinamide adenine dinucleotide phosphate 
(NADPH/NADP+). Through changes in cellular oxidation, iron is able to alter Sirtuin 1 
(Sirt1) activity to deacetylate serine threonine kinase B1(LKB1), which is known to 
cause a shift from nuclear to cytosolic localization to then increase activation of AMPK. 
iv 
 
Iron’s effects on oxidation also increase transcription of Peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC-1α), which promotes transcription of 
the rate-limiting enzyme in heme synthesis, Aminolevulinate synthase 1 (ALAS-1). 
Increases in heme levels increase the nuclear receptor subfamily 1, group D, member 2 
(Rev-Erbα) and nuclear receptor corepressor (NCOR) complex formation. The increased 
activity of AMPK and Rev-Erbα with increased dietary iron altered changes in whole 
body glucose metabolism by decreasing gluconeogenesis to improve glucose tolerance. 
These results indicate that dietary iron is able to modulate multiple pathways to alter 
glucose homeostasis, and suggest that more work is needed to gain a full understanding 
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Diabetes mellitus affects 347million people worldwide, and according to the 
American Diabetes Association costs 245 billion annually in the US alone (Danaei et al., 
2011). This group of metabolic diseases are defined by hyperglycemia but are also 
characterized by multiple abnormalities in lipid and protein metabolism. The principal 
forms of diabetes are type 1, type 2, and gestational. Type 1 diabetes is caused by the loss 
of pancreatic beta cells, usually from an autoimmune basis, and the central treatment 
strategy is insulin replacement. Type 2 diabetes (T2D) is a disease of peripheral tissue 
insulin resistance. Initially, beta cells of the pancreas increase insulin production to 
overcome that resistance, but as insulin resistance worsens, insulin production fails to 
maintain glycemia. This excessive production eventually leads to oxidative stress and 
beta cell death, which worsens glucose control. Gestational diabetes is similar to T2Ds 
and is triggered by the increased metabolic stress of pregnancy. 
 Of the three forms, T2D is the most prevalent, accounting for 90% of all cases 
worldwide. Although obesity is the strongest single risk factor for T2D, a complete 
understanding of the factors that lead to its development is lacking (WHO, 1999). Many 
environmental and genetic factors contribute to diabetes risk (Colditz et al., 1995; Kahn 





feeding (Huang et al., 2011; Gonnissen et al., 2013). The micronutrient iron has been 
shown to be connected to both irregular glucose metabolism and with maintenance of 
diurnal rhythms, although the mechanisms underlying this relationship are unknown. The 
aim of this dissertation is to explore various mechanisms through which dietary iron is 
able to modulate cellular metabolism and contribute to circadian rhythms.  
In this introduction, I will discuss studies that show a correlation between 
abnormal circadian rhythms and hyperglycemia. I will then explain the molecular 
components that regulate clock function, and the interplay of these transcriptional 
regulators with metabolism.  Finally, I will explain the relationship between iron and 
circadian rhythms, and briefly review my findings that dietary iron functions to regulate 
clock components. 
Circadian rhythms and glucose metabolism 
The connection between circadian rhythms and glucose homeostasis were first 
observed in case studies of shift workers. Numerous large cohort studies have shown 
increased risk of T2D in individuals who perform shift work for long periods of time 
(Spiegel et al., 2009; Pan et al., 2011). Moreover, chronic abnormal sleep patterns of 
either long (9 hours or more) or short (5 hours or less) duration are both associated with 
increased rates of T2D, hypertension, and high cholesterol (Ayas et al., 2003). These 
results are confounded by the fact that altered sleep patterns and shift work are also 
associated with higher body mass index (BMI) and adjustment for BMI in most studies 
removes the statistical significance for the association. These results suggest that the 





factors, including changes in the molecular clock, altered stress, social disruption, or 
other lifestyle factors.  
Changes in glucose homeostasis are also observed in short-term clinical studies 
of sleep deprivation. This was first shown by Spiegel  et al. (1999) who restricted the 
sleep of 11 healthy male volunteers, aged 18 to 27 years, to 4 hours for 6 consecutive 
nights. During the sleep deprivation, the subjects had a 40% increase in area under the 
glucose curve and insulin resistance when challenged with intravenous glucose 
administration, compared to a controlled rested state where the individuals were allowed 
to sleep for 12 hours. These studies were later repeated with a single night of sleep 
deprivation (4 hours of sleep within a 24-hour day) with insulin sensitivity measured by 
hyperinsulinemic euglycemic clamp  with infusion of [6,6-2H2]D-glucose (Donga et al., 
2010). The results of this clinical study found that a single night of restricted sleep led to 
a significant decreased glucose infusion, decreased glucose disposal, and increased 
endogenous glucose production.  
Other studies linking circadian rhythms with T2D include genome wide 
association studies (GWAS) and targeted haplotype analysis. Associations of T2D, 
metabolic syndrome, and hypertension have been noted with polymorphisms of circadian 
transcription factors Cry2, Clock, Per2, and a two-marker haplotypes of the Bmal1 
promoter (Woon et al., 2007; Dupuis et al., 2010). Another GWAS study showed an 
association between T2D and polymorphisms in a modulator of whole body synchrony, 
the melatonin receptor 1B. These melatonin receptor 1B polymorphisms were functional: 
When expressed in Hek293 cells, the receptor exhibited lower affinity for melatonin 





Causal relationships between glucose homeostasis and circadian rhythms have 
been established in animal models. Mice expressing a whole body mutation of the 
circadian transcription factor Clock in which exon 19 is missing due to a transversion 
(Clock∆19/∆19) have increased body weight, higher ad libitum glucose levels, lower ad 
libitum insulin levels, and worsened glucose tolerance (Turek et al., 2005; Marcheva et 
al., 2010). Moreover, targeted knock out models of the circadian transcription factor 
Bmal1 using either the albumin-cre to target the liver or Pdx-cre to target the beta cell are 
characterized by hypoglycemia or hyperglycemia, respectively (Lamia et al., 2008; 
Marcheva et al., 2010).  
Central and peripheral clocks 
A circadian rhythm is a 24-hour cycle of behavioral, and biochemical processes 
that are maintained by a system of transcription factor feedback loops. Circadian rhythms 
in behavior are regulated by light/dark cycles. Light excites the photopigment 
melanopsin, which is present in intrinsically photoreceptive retinal ganglion cells; when 
these cells depolarize, the impulse travels along the retinohypothalamic tract, to the 
suprachiasmatic nucleus (SCN) in the hypothalamus. The SCN is thought of as the 
central clock regulating circadian feeding, thermoregulation, and sleep/wake cycles. 
Lesion studies of the hypothalamus showed an ablation of circadian drinking behavior 
and activity (Mohawk et al., 2012; Steven and Zucker, 1972). Furthermore, the SCN 
maintains synchrony between the various clocks in peripheral tissues, and is thought to 






 Circadian rhythms in peripheral tissues were only discovered recently 
(Yamazaki et al., 2000; Yoo et al., 2004). Initially these peripheral clocks were thought 
to be regulated solely by the SCN; however, subsequent studies showed that timing in 
peripheral clocks could be shifted by other external signals called zeitgebers (time 
setters). One such study involved restricting the feeding of rats to an 8-hour period during 
the daytime, a shift from their normal crepuscular feeding patterns in the evening and 
early morning. In these rats, a luciferase reporter under the control of a Per1 promoter 
was used as a real-time measure of circadian rhythms. When these rats were restricted to 
daytime feeding, the peak expression of luciferase in the liver shifted by 12 hours, while 
the peak expression in the SCN was unchanged (Stokkan et al., 2001).  These results 
suggested not only that food is a zeitgeber for the liver clock, but also that peripheral 
tissues can become dyssynchronous from the central clock. Dyssynchrony between the 
SCN and peripheral tissues is the leading hypothesis as to why night shift workers have 
such a high incidence of metabolic disease and type 2 diabetes.  
Molecular components of circadian rhythm 
Much of the genome exhibits circadian expression with estimations from 
microarray studies showing that 10 to 50% of all genes exhibit rhythmic fluctuations; 
although the proportion of these directly affected by the core molecular clock is 
unknown, cycling in these transcripts may be largely due to factors downstream of the 
clock or due to behavioral rhythms (Panda et al., 2002; Yan et al., 2008). The core 
molecular clock is composed of both a positive and negative arm of transcriptional 
regulation. In mammals, the positive arm consists of the transcription factor brain and 





acetyl-transferase circadian locomotor output cycles kaput (Clock or its paralogue 
NPAS2), which heterodimerize and bind to an Ebox sequence in the promoter of clock 
controlled genes (CCGs) (Konopka and Benzer, 1971; Huang et al., 2011) (Figure 1.1).  
Some of the transcription factors that are positively regulated by the 
Clock/Bmal1 complex include the negative branch of circadian factors, including nuclear 
receptor subfamily 1, group D, member 1 (Rev-Erbα), Period (Per1, Per2), and 
Cryptochrome (Cry1, Cry2, Cry3). The nuclear receptor Rev-Erbα competes with the 
transcriptionally activating retinoic acid–related orphan receptor α (RORα) to bind to the 
ROR response element (RORE) in the Bmal1 promoter to repress its transcription in a 
complex with nuclear receptor co-repressor 1 (NCOR1).  More recently, an RORE has 
also been described in the Clock promoter (Crumbley and Burris, 2011). The second 
negative arm of circadian rhythms is comprised of period and cryptochrome proteins that 
heterodimerize in the cytosol and then are shuttled back into the nucleus to directly 
inhibit the function of the Clock/Bmal1 complex (Shearman et al., 2000; Lee et al., 2001; 
Sato et al., 2006).  
There are several posttranslational mechanisms that control this circadian 
feedback system, including phosphorylation, ubiquitination, O-linked glycosylation, and 
acetylation. The nuclear abundance of period and cryptochrome is regulated by a 
phosphorylation by casein kinase 1ε (CK1ε) or AMPK, respectively, which tags them for 
polyubiquitylation by the E3 ubiquitin ligase complex β-transducin repeat containing 
protein (β-TrCP1), and F-box and leucine-rich repeat protein 3 (FBXL3), which leads to 
their subsequent degradation by the 26S proteasome (Akashi et al., 2002; Eide et al., 





nuclear translocation of the Per/Cry complex, and may be important in some of the 
inhibitory properties (Meng et al., 2010). Degradation of Per2, Clock and Bmal1 is 
countered by O-linked glycosylation to regulate circadian timing (Kim et al., 2012; 
Kaasik et al., 2013; Li et al., 2013). Finally, acetylation of Bmal1 facilitates 
cryptochrome interaction with this complex to affect its repression (Hirayama et al., 
2007; Asher et al., 2008).  
Recently, this canonical control of circadian rhythms by transcriptional 
regulation has been challenged by the discovery of a circadian rhythm in anucleated red 
blood cells. Red blood cells maintain a circadian rhythm in the oxidative state of certain 
proteins peroxiredoxin and haemoglobin (O’Neil and Reddy, 2012). Other cell types also 
have redox cycles; however, they are thought to function downstream of the 
transcriptional regulators, as seen in the SCN where redox signals function to regulate the 
excitability of neurons (Wang et al., 2012).  
Cross-regulation between circadian rhythms and metabolism 
The leading hypothesis as to why circadian rhythms are evolutionarily 
advantageous is that they synchronized energy utilization and energy availability. Much 
of the rationale behind this hypothesis is found by assessing known circadian controlled 
pathways including genes important in cell division, and the biochemical pathways that 
produce cellular components such as glucose and lipid homeostasis necessary for 
nucleotide, amino acid, and phospholipid synthesis (Matsuo et al., 2003). Members of the 
core molecular clock directly control metabolism, including Rev-Erbα, which is known to 
regulate gluconeogenesis, adipogenesis, and lipogenesis (Lau et al., 2004; Canaple et al., 





activated receptor (PPAR) family members α and γ that regulate lipid utilization and 
storage, respectively (Duez and Staels, 2008). 
Metabolic pathways also regulate circadian rhythms, and indeed the interaction 
between the two pathways was first described with the observation that a lower 
NAD/NADH ratio enhanced Clock/Bmal1 heterodimerization as well as DNA binding 
(Rutter et al., 2001). Also, the metabolic master regulator AMPK directly phosphorylates 
Cry1 to cause its degradation, and regulates nicotinamide phosphoribosyltransferase 
(NAMPT) the rate-limiting enzyme in NAD+ biosynthesis pathway (Cantó et al., 2009; 
Lamia et al., 2009). The biosynthesis of NAD+ feeds into circadian rhythms through the 
deacetylase Sirtuin 1 (Sirt1), which utilizes NAD energy stores for deacetylation. Sirt1 is 
thought to complex with Clock and Bmal1 to alter Per2 acetylation to promote its 
degradation as well as to regulate histone mobility (Asher et al., 2008).  
Circadian rhythms and iron 
There is evidence that iron is both regulated by and regulates circadian rhythms. 
Systemic iron levels fluctuate in a circadian manner as do iron-bound proteins and 
proteins important in iron metabolism (Rubio et al., 2003; Unger et al., 2009). Moreover, 
in microarray studies attempting to elucidate the downstream targets of the molecular 
clock of the SCN by performing a 15-minute light-pulse on mice in the middle of the 
dark phase, 10% of the genes that were changed were associated with iron and heme 
metabolism (Ben-Shlomo et al., 2005).  
There is also evidence that iron may be necessary for maintenance of circadian 
rhythms of the SCN that regulates behavioral rhythms. In humans, low iron stores and 





(RLS), a circadian disorder characterized by the uncontrollable urge for leg movement 
(Earley et al., 2005). In rats fed an iron deficient diet for 28 days, there was a decrease in 
motility and a shift of the diurnal peak in body temperature (Youdim et al., 1980). These 
results could be due to irons effects on the dopaminergic response, or due to iron’s effects 
on other central clock outputs such as its control of the cellular localization of melatonin 
(Pablos et al., 1996). Finally, drosophila with knockdown of the light chain of ferritin 
were unable to maintain circadian movement in dark conditions and rhythm in circadian 
transcripts clock, period, and timeless was disrupted in the heads of these flies 
(Mandilaras and Missirlis, 2012). Recently, it has been suggested that iron may also play 
a more direct role in circadian rhythms when it was shown to control period length in 
Arabidopsis thalia, and iron deficiency altered the cycling of molecular clock 
components (Chen et al., 2013). 
Iron also has the ability to affect the concentration of heme, a cofactor reported to 
bind in a regulatory manner to several circadian components, including Rev-Erbα, 
NPAS2, and Per2 (Yin et al., 2007; Kitinashi et al., 2008). In erythrocytes, iron activates 
an iron regulator protein that will bind to an iron-responsive element in the 5’ 
untranslated region of ALAS2, the erythroid-specific rate-limiting enzyme in heme 
synthesis (Ajioka et al., 2006).  An ubiquitously expressed isoform of this heme 
synthesis-regulating enzyme, ALAS1, does not have an iron-response element but does 
have circadian oscillations of its transcripts that are regulated by PGC-1α (Estall et al., 






Summary of findings 
In this introduction, I have provided evidence that circadian rhythms regulate 
glucose homeostasis, and that iron affects circadian rhythms and we will further expand 
upon the relationship that iron itself has in whole body glucose homeostasis, as well as 
introduce its regulation of AMPK in Chapter 2. In this dissertation, we will also describe 
that dietary iron alters AMPK phosphorylation through oxidative regulation of Sirt, as 
well as explore irons regulation of cellular redox state to assess its effects upon heme 
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DIETARY IRON CONTROLS CIRCADIAN RHYTHM OF  




The circadian rhythm of the liver is important in the maintenance of glucose 
homeostasis, and disruption of this rhythm is associated with type 2 diabetes risk. 
Feeding is one factor that sets the circadian clock in peripheral tissues, but relatively little 
is known about the role of specific dietary components in that regard.  We have assessed 
the effects of dietary iron on the circadian rhythm of gluconeogenesis. Dietary iron 
affects circadian glucose metabolism through heme-mediated regulation of the interaction 
of Rev-Erbα with its cosuppressor NCOR. Loss of regulated heme synthesis was 
achieved by aminolevulinic acid (ALA) treatment of mice or cultured cells, to bypass the 
rate-limiting enzyme in hepatic heme synthesis, ALAS1. ALA treatment abolishes 
differences in hepatic glucose production and in the expression of gluconeogenic 
enzymes seen with variation of dietary iron. The differences among diets are also lost 
with inhibition of heme synthesis by treatment with isonicotinylhydrazine (INH). Heme 
levels respond to dietary iron through modulation of the level of PGC-1α, a 





acetylcysteine (NAC) diminishes the PGC-1α variation observed among the iron diets, 
suggesting that iron may be acting through reactive oxygen species signaling to regulate 
PGC-1α. Together, these studies show that dietary iron alters the circadian rhythm of 
metabolism through control of intracellular heme synthesis. 
Introduction 
Circadian rhythms are endogenous cycles of behavioral and physiological 
processes that are set by external signals called zeitgebers. Light is the zeitgeber for the 
central clock of the suprachiasmatic nucleus (SCN) that controls circadian movement, 
feeding behavior, and thermoregulation (Buhr et al., 2010). These contribute to the 
synchronization of clocks in peripheral tissues, but peripheral clocks also entrain to non-
SCN zeitgebers. Notably, the liver is entrained to food intake and can become 
dyssynchronous from the SCN (Damiola et al., 2000; Stokkan et al., 2001). Such 
dyssynchrony may contribute to the observed association between metabolic 
dysregulation and altered sleep rhythms or night shift work (Huang et al., 2011). 
The precise contribution of specific nutrients to setting the hepatic clock is 
incompletely understood. One micronutrient, iron, has significant effects on metabolism. 
Iron affects metabolic regulation through multiple mechanisms, including effects on 
AMP-dependent kinase, fuel preference, insulin secretion, and regulation of the insulin-
sensitizing adipokine, adiponectin (Huang et al. 2007, Gabrielsen et al. 2012). Iron 
overload and excess dietary iron are also significant risk factors for diabetes (Fernandez-
Real et al., 2002; Bowers et al., 2011; Qui et al., 2011; Simcox and McClain, 2013). Iron 
is a particularly attractive candidate for contributing to changes in circadian metabolism: 





transport and metabolism, but several circadian transcription factors bind heme. Heme, 
for example, is necessary for the formation of the complex of nuclear receptor subfamily 
1 group d member 1 (Rev-Erbα) with Nuclear Receptor Co-Repressor 1 (NCOR), part of 
the negative arm of the circadian transcriptional feedback loop (Li et al., 2007, Raghuram 
et al., 2009). Heme has also been reported to bind Clock and Per2, although the 
functional relevance of this binding is unknown (Kaasik & Lee, 2004; Kitanishi et al., 
2008; Airola et al., 2010; Lukat-Rogers et al., 2010). 
To test the hypothesis that dietary iron intake may affect circadian metabolic 
rhythms, we fed mice chow with various iron concentrations, creating tissue iron levels 
within the range found from normal variation in human diets. We demonstrate that 
dietary iron content affects gluconeogenesis and circadian rhythm through modifying 
hepatic heme levels with concordant changes in Rev-Erbα binding to NCOR. Iron elicits 
these effects through Peroxisome Proliferator-  
(PGC-1α)-mediated regulation of the rate-limiting enzyme of heme synthesis in non-
erythroid cells, aminolevulinic acid synthase (ALAS1).  
Results 
Dietary iron affects circadian glucose metabolism 
To assess the effects of dietary iron on circadian glucose utilization, we 
performed glucose tolerance tests (GTTs) at 6-hour intervals in separate cohorts of fasted 
(6-hour) C57BL/6J male mice fed high (H, 2g iron/kg chow), high normal (HN, 500mg 
iron/kg chow), or low normal (LN, 35mg iron/kg chow) iron diets for 6 weeks. These 
levels of dietary iron allowed normal hemoglobin concentrations and red blood cell 





liver iron concentraions, with an ~3-fold difference between mice fed the LN compared 
to H iron diets (Table 4.1). Fasting glucose and area under the glucose curve (AUCg) 
during glucose tolerance testing varied significantly with time, as has been reported 
previously (Ben-Dyke et al., 1971; Zimmet et al., 1974). Additionally, glucose values 
differed among the dietary groups, with significant differences in fasting glucose values 
at ZT18 and in AUCg at ZT0 and ZT12 (4.S.1A and B). 
To elucidate the mechanism behind these differences in glucose, we first 
measured ad libitum circulating insulin levels and saw no variation between the diets that 
would explain the changes in glucose metabolism (Table 4.1). We next assessed 
gluconeogenesis because it is a major contributor to serum glucose concentrations, and its 
dysregulation is seen early in diabetes. We have previously reported that high dietary iron 
significantly decreases gluconeogenesis (Huang et al., 2013).  We validated these data 
with an in vivo measure of gluconeogenesis, the pyruvate tolerance test (PTT), performed 
at ZT12 when mice normally begin feeding and down regulate gluconeogenesis (Figure 
4.1A and B). Mice fed the LN diet exhibited higher levels of blood glucose in response to 
pyruvate injection compared to mice on the HN or H diets. Variations in glucagon did not 
account for these differences (Table 4.1). The LN-fed mice weighed 1.8 and 1.2 g more 
than the HN- and H-fed mice, respectively (Table 4.1). This difference in weight, 
however, did not account for the differences in PTT as weight and AUCg were not 
significantly correlated across all individuals (p=.3944, not shown).  
We next assessed the transcript levels of gluconeogenic genes in the livers of the 
mice on the different iron diets. Consistent with the AUCg after pyruvate tolerance 





significantly greater peak in mice on the LN diet when compared to the H- and HN-fed 
mice (Figure 4.1C). Glucose-6-phosphatase (G6Pase) peak levels trended higher in the 
LN compared to the H group (Figure 4.1D). For both transcripts, the magnitude of the 
variation over the 24-hour period is less in the H-fed mice compared to the LN group. 
The HN group is similar to the H group for PEPCK and to the LN group for G6Pase. 
Feeding behavior did not differ significantly among these groups (4.S.1C).  
Iron alters Rev-Erbα repressor complex formation and activity 
Because the parameters of glucose homeostasis exhibited temporal fluctuations 
that were dependent on dietary iron content, we next examined circadian regulatory 
factors that are associated with iron. Rev-Erbα is a member of the circadian regulon that 
directly inhibits PEPCK and G6Pase expression. This repressive activity requires heme 
for Rev-Erbα to bind NCOR to form the repressor complex (Yin et al., 2007). We 
assessed complex formation at ZT14, a time when circadian repression of gluconeogenic 
enzyme expression is beginning to manifest, by performing an immunoprecipitation of 
Rev-Erbα followed by immunoblotting for NCOR. We observed a direct correlation of 
complex formation with increased dietary iron (Figure 4.2A and B), consistent with the 
observed decreases in gluconeogenesis and levels of gluconeogenic enzyme transcripts 
with higher dietary iron. Complex formation correlated with occupancy at ZT14 of the 
PEPCK and G6Pase promoters by NCOR, as revealed by chromatin immunoprecipitation 
(ChIP) (Figure 4.2 C and D). At ZT14, we did not observe variations in Rev-Erbα 






Dietary iron alters heme levels and temporal expression  
of enzymes involved in heme synthesis 
 and degradation 
The heme dependence of Rev-Erbα/NCOR repressor complex formation 
prompted us to measure hepatic heme levels. Mice were maintained on the various iron 
diets for 9 weeks then sacrificed. Their livers were perfused with PBS to remove red 
blood cells, and total heme levels were assessed by HPLC (Figure 4.3A and 4.S.3A). A 
pyridine hemochromagen assay was performed to determine levels of heme b, the form 
that binds Rev-Erbα (Figure 4.3B and 4.S.3B) (Li et al., 2011). In all three assays, heme 
was highest in the H-fed mice at ZT12, which was the time at which we observed arise in 
Rev-Erbα/NCOR complex formation (Figure 4.2B and D). Conversely, at ZT0, heme 
levels were highest in the LN-fed mice and significantly lower in the HN- and H-fed 
mice (4.S.3A and 3B)). The net result of these changes is that heme b levels show higher 
circadian variation in mice fed higher iron diets, as reflected in the ZT12/ZT0 ratios 
(LN=.778, HN=1.69, and H=3.02). This same pattern of variation was observed in the 
total heme, and in addition, the LN total heme levels peaked at ZT0 while the HN and H 
heme levels peaked at ZT12 (not shown). Peak transcript levels of  ALAS1 (Figure 4.3E) 
increase with increased heme at ZT10, and heme oxygenase 1 (HO-1), an enzyme 
necessary for heme catabolism (4.S.3C), also increased with increasing dietary iron at 
ZT18.  
If ALAS-1-mediated changes in heme levels are driving the changes in Rev-
Erbα/NCOR association, we hypothesized that bypassing ALAS-1 should increase heme 





heme synthesis should decrease heme levels, likewise limiting the effects of dietary iron 
but with an opposite effect on gluconeogenesis. Treatment of mice with the product of 
ALAS1, aminolevulinic acid (ALA) has been shown to increase heme levels in the liver 
and erythrocytes (Phillips et al., 2000). Mice were therefore fed the LN, HN, and H iron 
diets for 9 weeks; for the last 3 weeks before harvest, they were concurrently treated with 
2mg/mL ALA in their drinking water. No variations in water intake were observed 
between treated vs control mice (not shown). At the end of this period, we determined 
heme levels in perfused liver by HPLC. Heme levels increased in all three diets (Figure 
4.4A). Heme b levels showed a similar trend (4.S.2). We performed PTTs on the ALA 
treated and control mice at ZT12; ALA treatment abolished differences between the LN-, 
HN-, and H-fed mice (Figure 4.4B). ALA treatment also diminished the differences in 
PEPCK and G6Pase mRNA levels observed in the control mice with the various iron 
diets (Figure 4.4C and D). In general, the effect of ALA treatment was to decrease the 
PTT-AUCg and transcript levels in the LN mice toward the levels seen in the mice on the 
higher iron diets. Furthermore, IP of Rev-Erbα in ALA treated and control livers showed 
increased NCOR coprecipitation with ALA treatment in all groups (Figure 4.4E). The 
relative effect of ALA treatment on Rev-Erbα/NCOR complex formation was greatest in 
the LN mice, while the H-fed mice showed no effect of ALA treatment. The data are 
consistent with heme synthesis being limiting for circadian rhythmicity on lower iron 
diets but less so on the higher iron diets.  
Isonicotinylhydrazine (isoniazid, INH) inhibits heme synthesis by decreasing 
pyridoxine, a cofactor for ALAS1. Mice were fed the iron diets for 8 weeks and then 





variations in water intake were observed in treated compared to control mice (data not 
shown). PTT was performed after 5 days of INH treatment, and tissues were harvested 
after 10 days. The results were the converse of those observed on ALA: The effect of 
INH was to increase the lower AUCg seen in the HN and H diets to a level resembling 
that observed in the mice on LN diet (Figure 4.4H). Similar effects were noted for 
PEPCK and G6Pase transcript levels (Figure 4.4I and J) seen in the HN and H diets up to 
those observed in the mice on the LN diet, also consistent with the hypothesis that heme 
is mediating the effects of dietary iron; the effects of inhibiting heme synthesis with INH 
were less marked in the LN mice who started with lower heme levels than in the HN and 
H groups that started with higher heme levels. The INH treatment also decreased Rev-
seen in the H group (Figure 4.4K and 4L).  
Dietary iron acts directly on the hepatocyte to alter  
gluconeogenesis 
To determine if dietary iron directly affects hepatocyte glucose production as 
opposed to exerting more indirect (e.g., hormonal) effects, we treated HepG2 cells with 
ferric ammonium citrate (FAC). Cells were grown for 12 hours in control DMEM or 
DMEM with 10µM FAC, with or without treatment of ALA or INH. We then set a 
circadian rhythm in the cells with 100nM dexamethasone (DXS) shock (Balsilobre et al., 
2000). The results were concordant with in vivo results. At the peak expression of 
PEPCK and G6Pase, non-iron-treated cells exhibited a greater PEPCK and G6Pase 
expression compared to the FAC treated cells (Figure 4.5A and B). These differences 





PEPCK and G6Pase transcript levels down in non-iron-treated cells, close to those 
observed in the FAC-treated cells (Figure 4.5A and B, left panels). Conversely, INH 
increases transcript levels in the FAC treated cells, close to those observed in non-iron-
treated cells (Figure 4.5A and B). During the peak times, we also assessed NCOR 
association with Rev-Erbα through a coimmunoprecipitation and were able to 
recapitulate the trends observed in the animals: FAC treatment increased association of 
NCOR and Rev-Erbα (Figure 4.5C and D, middle panel). ALA treatment increased 
complex formation to levels seen in the FAC-treated cells, while INH treatment 
decreased association to levels seen in the non-iron-treated cells (Figure 4.5C and 5D). 
Variations in heme synthesis are due to differences  
in PGC-1α expression related to altered oxidative  
signaling in mice on the different iron diets 
 PGC-1α regulation of ALAS1 transcription (Estall et al., 2009) led us to 
explore its possible regulation by iron to explain the differences in heme synthesis 
between the iron diets. In mice, both PGC-1α transcript and protein levels increased with 
increasing dietary iron (Figure 4.6A-C). In HepG2 cells, partial silencing of PGC-1α by 
siRNA treatment (Figure 4.6D) ablated the differences in ALAS1, PEPCK, and G6Pase 
that occurred with FAC treatment (Figure 4.6E, 6F, and 6G).  
PGC-1α is up regulated by reactive oxygen species (ROS) (Wu et al., 1999; Lin 
et al., 2005; Marmolino et al., 2010), and iron is known to create ROS through fenton 
chemistry. Therefore, we explored oxidative signaling as a mechanism through which 
dietary iron up regulates PGC-1α. Cellular oxidative markers differed temporally among 





in the H fed mice. To blunt differences in oxidant levels among mice on the iron diets, we 
treated them with the antioxidant N-acetylcysteine (NAC). Mice began their respective 
iron diets at 3 months of age and remained on the diets for 9 weeks, at which time they 
were split into a control and NAC treated group. The NAC treatment was administered in 
the drinking water of the animals for 10 days at levels of 40mM. No variation in water 
intake was observed between the treated group and control (not shown). The livers of the 
mice were harvested at ZT12. NAC treatment abolished differences in PGC-1α, PEPCK, 
G6Pase, ALAS1, GSH, and NADPH/NADP+ ratios between the diets (Figure 4.7C-7H).  
Discussion 
Iron is a risk factor for several parameters of metabolic syndrome. For example, 
a high serum ferritin level, a marker of tissue iron stores, is associated with insulin 
resistance and type 2 diabetes (Ford and Cogswell, 1999; Forouhi et al., 2007). Likewise, 
high iron is associated with gestational diabetes, high triglyceride levels, steatohepatitis, 
and cardiovascular risk (Kiechl  et al., 1994; Tuomainen et al., 1998; Qui et al., 2011; 
Kim et al., 2013). Another hallmark of metabolic syndrome, obesity, is more prevalent in 
individuals with iron deficiency, although there is conflicting evidence as to whether this 
is related to low iron causing obesity or obesity causing decreased iron absorption 
(Pinhas-Hamiel et al., 2003; Sonnweber et al., 2012). This relationship between iron and 
metabolic syndrome highlights the role of iron as both a structural component of proteins 
involved in fuel metabolism and bioenergetics, and as a cellular regulator of metabolic 
pathways such as adiponectin transcription and AMPK activity (Gabrielsen et al., 2012; 
Huang et al., 2013). We show herein yet another role of iron in metabolism, namely that 





synthesis that in turn affects the activity of a key component of the circadian machinery, 
Rev-Erbα.  
Besides being a crucial component of the circadian clock, Rev-Erbα regulates 
many aspects of glucose and lipid metabolism, including acting as a negative 
transcriptional regulator of gluconeogenic enzymes. Decreased Rev-Erbα expression is 
associated with hyperglycemia and obesity in mice and humans (Yin et al., 2007; Cho et 
al., 2012; Delezie et al., 2012; Goumidi et al., 2012). Previous work has shown that Rev-
Erbα activity is dependent on the formation of a repressor complex with NCOR, which 
requires heme (Yin et al., 2007). We verified the dependence of this complex formation 
on heme availability, and further showed that liver heme levels are increased in a 
circadian fashion with increased dietary iron. The results demonstrate that heme 
availability is altered by dietary iron and is a regulating factor in the circadian rhythm of 
hepatic gluconeogenesis. While heme is known to be required for Rev-Erbα/NCOR 
complex formation, the observations that heme availability is limiting for that process in 
normal physiologic circumstances has not been previously shown. 
The changes in heme levels observed with increased dietary iron are not due to 
limiting amounts of iron for metalation of heme but rather by the regulation of heme 
synthesis by ALAS1. This is revealed by the facts that bypassing ALAS1 with ALA, or 
inhibiting heme synthesis by INH, abrogated the effects of dietary iron. If iron itself were 
limiting in the LN diet, for example, ALA would not be able to increase heme-dependent 
formation of the Rev-Erbα/NCOR complex in mice on that diet. Furthermore, mice on 
the lower levels of dietary iron show no evidence of systemic iron deficiency, in that they 





(Table 4.1). ALAS-1 itself exhibits a circadian rhythm controlled by PGC-1α and its 
binding partners NRF-1 or FOXO1 (Handschin et al., 2005). We confirmed this circadian 
rhythmicity in the current study and show that the magnitude of its excursions is 
significantly altered by dietary iron. The regulation of ALAS1 is not mediated directly by 
iron responsive proteins, as it is for the erythroid form of the enzyme ALAS2 (Ajioka et 
al., 2006). Rather, iron drives increased PGC-1α expression that in turn transcriptionally 
activates ALAS-1. This was demonstrated by the fact that the effects of iron on ALAS-1, 
PEPCK, and G6Pase were not seen after knockdown of PGC-1α.  
A decrease in PGC-1α transcript and protein levels in the skeletal muscle of rats 
fed iron deficient diet has been previously observed, although the mechanism of this 
change was not determined (Han et al., 2011). We demonstrate that iron regulation of 
PGC-1α occurs at least in part through oxidant sensing pathways. Mice on the higher iron 
diets show evidence of changes in intracellular redox state as revealed by decreased GSH 
and decreased NADPH/NADP ratios. Treatment of mice with the antioxidant N-acetyl 
cysteine eliminated the variation seen in PGC-1α, ALAS-1, PEPCK, and G6Pase among 
the different iron diets. The levels of GSH and NADPH/NADP ratio significantly varied 
between the iron diets at specific time points, and treatment with NAC ablated the 
differences between the groups. These data suggest that dietary iron is acting through 
ROS to exert effects upon heme synthesis and subsequently gluconeogenesis. Recent 
research has focused on ROS not solely as potentially damaging or toxic entities, but also 
as an intracellular signaling pathway by which the bioenergetic and metabolic status of 
the cell is sensed for purposes of altering processes such as fuel choice, stress response, 





Average PEPCK and G6Pase transcript levels are greater in mice fed the LN 
iron diet compared to the H-fed group. The levels of G6Pase transcripts in the HN mice, 
however, are similar to those of the LN mice, while the levels of PEPCK in the HN mice 
are similar to the H-fed mice (Figure 1E and 1F). This variation in response to iron may 
be due to other signaling pathways: Differential regulation of PEPCK and G6Pase, for 
example, is also signaled by insulin and by the forkhead transcription factors (Barthel and 
Schmoll, 2003). Thus, the variation in these responses, in the differences of PEPCK and 
G6Pase promoter occupancy seen in the ChIP assays, and in the incomplete effects of 
ALA and INH treatments on heme and levels and gluconeogenic transcripts (Figures 4.3 
and 4.4) highlight the fact that the regulation of gluconeogenesis is multifactorial, 
complex, and responsive to many influences beyond iron and oxidative stress. 
We chose the specific levels of iron in the diets employed in this study for 
several reasons. The LN diet is derived from the dietary recommendations of the 
American Institute of Nutrition as specified in their AIN93G diet, which has levels of 
iron and other nutrients that are sufficient for normal growth, pregnancy, and lactation 
(Reeves et al., 1993). This diet is commonly used as the normal chow in laboratories that 
investigate the effects of iron on physiology and development (Jang et al., 2000; Reeves 
et al., 2004; Nam and Knutson, 2012). The level of iron in the HN diet is based on other 
“normal” diets commonly used in animal facilities, with batches of these diets ranging in 
iron content from 300mg/kg to 600mg/kg (Committee on animal nutrition, 1995). The H 
diet was selected because the mice have liver iron stores that are only modestly increased 
above that seen on the “normal” chows, namely 2-fold (Table 4.1). This is within the 4–





(Milman et al., 1986; Catiella et al., 2012). Serum ferritin, the most commonly used 
measure of tissue iron stores, varies over a range of ~15-fold in normal humans (Koziol  
et al., 2001). Thus, our results demonstrate that iron exerts regulatory influences on 
metabolism even within its “normal” range.  
Previous work on iron and metabolism has concentrated on pathologic iron 
overload. Hereditary hemochromatosis and β-thalassemia, for example, have long been 
known to be associated with type 2 diabetes (Brittenham et al., 1994; Cooksey et al., 
2004; Hatunic et al., 2010). More recently, however, it has become clear that increased 
diabetes risk is also seen with more modest levels of iron excess such as are seen in 
normal individuals with higher levels of dietary iron intake or in those taking iron 
supplements (Jiang et al., 2004; Bowers et al., 2011; Qui et al., 2011). On the surface, 
this correlation of high iron with increased diabetes risk appears contradictory to our 
results of high iron being associated with improved glucose tolerance and hepatic glucose 
production. However, type 2 diabetes is a multifactorial disease involving insulin 
resistance (most often related to obesity), insulin deficiency, and metabolic abnormalities 
in multiple tissues. Thus, prodiabetic effects of iron on insulin production and adipokines 
may over time overwhelm other apparently antidiabetic effects such as those observed on 
hepatic gluconeogenesis (Jouhani et al., 2008; Gabrielsen et al., 2012). It is also possible, 
however, that the increased magnitude of circadian variation in hepatic gluconeogenesis 
seen in the high iron fed mice could be prodiabetic under certain circumstances. For 
example, in situations of nightshift work, sleep disturbance, or snacking during the night, 





2012), it might be expected that individuals with higher iron would suffer greater 
dyssynchrony and disruption of normal metabolic regulation. 
Besides its effects on ROS and heme availability, the effects of iron on 
metabolism are likely to be widespread and not explained by a single mechanism. We 
have previously shown, for example, regulation of insulin production, adiponectin, and 
AMP-dependent kinase by iron (Jouihan et al., 2008; Gabrielsen et al. 2012; Huang et 
al., 2013). The current studies suggest yet other possible effects of iron. In the INH 
treated mice, for example, even with complete ablation of the differences in heme levels 
in mice on the three diets, there were still differences noted in the Rev-Erbα repressor 
complex formation. This suggests that there may be factors other than heme by which 
iron alters Rev-Erbα/NCOR complex formation. The drosophila Rev-Erbα homologue 
E75 is regulated by nitric oxide (NO) (Cáceres et al., 2011), and transcript levels of nitric 
oxide synthase, the rate-limiting enzyme in NO synthesis, were increased with increasing 
dietary iron at certain time points (not shown). Further, the redox state of thiols within the 
heme-binding pocket of proteins such as Rev-Erbα also regulates heme binding 
(Ragsdale and Gupta, 2011; Shimizu, 2012). Therefore, the altered redox state of the cells 
seen in the various iron diets may also play a role in heme binding to Rev-Erbα. Finally, 
the activities of other heme-binding proteins such as Rev-Erbβ, another member of the 
Rev-ErbA family of transcription factors, are also likely to be altered by dietary iron. 
Thus, future studies to assess these pathways are justified, as are the effects of iron on 
other metabolic pathways such as lipid synthesis and in other tissues.  
Although our work has focused on one metabolic process, hepatic 





plants (Chen et al., 2013) and insects (Mandilaras and Missirlis, 2012), and they are 
manifest in multiple organ systems and tissues, including the central clock of the SCN. 
Iron deficiency in mice, for example, alters thermoregulation, behavior, and monoamine 
metabolism and dopamine transporter expression in the central nervous system (Youdim 
et al., 1981; Bianco et al., 2009). Furthermore, knockdown of the drosophila homologue 
of ferritin in circadian neurons disrupts the molecular components of the central clock 
(Mandilaras and Missirlis, 2012).  Other studies have shown that heme synthesis by the 
liver is capable of affecting pineal gland secretion of melatonin, suggesting that dietary 
iron will have further, perhaps sweeping, effects on physiology beyond that of hepatic 
control of gluconeogenesis (Puy et al., 1996).  
In summary, we have demonstrated that one mechanism through which dietary 
iron is able to regulate the core molecular clock in the liver is through regulation of heme 
synthesis. This novel role of iron provides another mechanism through which iron acts to 
regulate glucose metabolism. The studies suggest mechanisms that may underlie the 
interplay among iron, altered circadian rhythms, metabolic regulation, and diabetes risk.  
Materials and methods 
 
Animal studies 
Three-month-old male C57BL6/J mice were fed diets of 35 mg/kg, 500 mg/kg, or 
2 g/kg carbonyl iron (Harlan Teklad Madison, WI) for 6 weeks before in vivo 
physiological testing and 9 weeks before sacrifice. The animals were maintained on a 12-
hour light/dark cycle. Treatment of mice was with 2mg/mL ALA (Frontier Scientific 





#A9165) in their drinking water and adjusted to pH 7. ALA treatment began after 6 
weeks on diet and continued  for 3 weeks concurrent with continued time on diet. Mice 
were treated with NAC or INH for 10 days after 8 weeks on diet. Prior to GTT, mice 
were fasted for 6 hours and then challenged with 1mg glucose per gram body weight 
through IP injection. Mice were not fasted prior to PTT because fasting has been shown 
to modulate circadian control of hepatic gluconeogenesis. For PTT, mice were challenged 
with 2mg pyruvate per gram body weight through IP injection. Procedures were approved 
by the Institutional Animal Care and Use Committee of the University of Utah and the 
Veterans Administration. 
Cell culture 
 HepG2 cells (ATCC) were maintained in Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 supplemented (DMEM/F12) with 10% fetal bovine serum and 1% 
primocin. The cells were plated on 6 well plates overnight and then treated with 10μM 
FAC, 2mM ALA, 1mM INH or a PBS no treatment control for 12 hours.  After the drug 
or iron treatment, the plate was synchronized with a 100nM dexamethasone (DXS) shock 
for 1-hour; after this time, the media was removed, the cells washed with PBS 2x, and 
DMEM/F12 with treatment was replaced. Cells were harvested at 4-hour intervals from 
the time of shock for 48 hours. Knockdown of PGC-1α was accomplished by PGC-1α 
siRNA from Santa Cruz Biotech (sc-38885), following the company’s general protocol 







  RNA was isolated from liver samples using RNeasy Mini Kit (Qiagen) and bead 
mill tubes with 1.44mm ceramic beads; cDNA synthesis was performed with superscript 
III first-strand synthesis system (Invitrogen). Measurement of both RNA and cDNA was 
performed by nanodrop (EPOCH), and quantification of cDNA was performed by real-
time PCR analysis using the Power SYBR Green Master Mix (Applied Biosciences). 
Primers were designed using the NIH facilitated Mouse Primer Depot (Simcox, 2009-
2014 http://mouseprimerdepot.nci.nih.gov/).  
Western blotting 
Antibodies used included Rev-Erbα (Santa Cruz Biotechnologies Inc.), NCOR, β-
actin (Cell Signaling), and PGC-1α (Abcam). The Criterion running and transfer system 
with precast gels was used (BioRad). 
Heme measurement 
Heme was measured by pyridine hemochrome spectrophotometric assay and 
HPLC as described (Sinclair et al., 1999). In the pyridine hemochrome assay, heme was 
extracted from tissue samples with 500mM NaOH and samples were normalized to 
protein concentrations and brought up to 600µL volume after which pyridine was added 
to make a 40% solution. Initial wave scans were performed from 450 to 620nm using an 
Ultrospec 3000 spectrophotometer; this was repeated after addition of 1M potassium 
ferricyanide and sodium dithionite crystals. Data were collected with Biochrom DC 
software and analyzed using published extinction coefficients (Trumpower and Berry, 





Acetone acidified with 2.5% HCl, filtered (0.45uM) and HPLC measurements performed 
on a Waters 2690 pump with C18 reverse phase column (39X300mm Waters 
µBondapak) and C18 precolumn (Water 2690; Water 996 phospho-diode array detector). 
Samples (0.125ul) were eluted over a 15-minute period using a linear gradient of 60% 
buffer A (.56mM NH4H2PO4, ph 7.0) to 100 % buffer B (100% Methanol), visualized 
with a Waters 996 phospho diode array detector at 400nm and quantified with external 
standards. 
ChIP 
ChIP studies were performed as previously described using the Simple ChIP kit 
with company modifications for tissue samples (Cell Signaling Technology; Gabrielsen 
et al., 2012). Liver samples were homogenized in bead mill tubes with 1.44mm ceramic 
beads and then cross-linked for 20 minutes with 1% formaldehyde, the crosslinking was 
stopped with glycine, and the lysates were sonicated 3x for 20 seconds using a sonic 
dismembrator (Fisher Scientific). Lysates were precleared with salmon sperm blocked 
protein A/G agarose beads (Millipore). Each sample IP was performed in duplicate.  
NCOR, Igg, or Histone H3 antibody (Cell signaling) was applied for 1 hour at room 
temperature. DNA was released from protein-DNA complexes by proteinase K digestion 
and quantified by real-time PCR for the enrichment at the PEPCK and G6Pase promoter 
as well as using GAPDH and the PEPCK gene as negative controls using the Power 
SYBR Green Master Mix (Applied Biosciences; Yin et al., 2007). Occupancy was 







Liver protein lysates isolated in a standard HEPES lysis buffer were precleared 
with Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnical Inc.). Rev-Erbα 
antibody (Santa Cruz Biotechnical Inc.) or a negative control Igg (Cell signaling) in 1x 
PBS was incubated with end over end mixing for 4 hours at 4˚C with Protein A/G PLUS-
Agarose beads. The beads were washed 5x with PBSCM (PBS buffer (100 mM sodium 
phosphate, 150 mM NaCl, pH 7.2) with 1 mM CaCl2 + 1 mM MgCl2). The protein 
lysate samples were then incubated with the beads overnight. Following protein 
incubation, the beads were washed 5x with PBSCM and then samples were eluted with 
sample loading buffer and incubation at 100˚C for 5 minutes.  
Metabolite measurement 
 This procedure was done as previously described (Huang et al., 2013). Briefly, 
20mg of freeze clamped tissue was homogenized in bead mill tubes containing 500µL of 
cold 90% MeOH containing internal standards. After a 20,000xg centrifugation, the 
supernatant was collected and a second extraction step was performed on the pellet with a 
cold 60% MeOH solution.  The supernatants were combined and vacuum dried. Two 
Shimadzu LC10AD VP pumps and a CTO-10AS column oven were used for HPLC 
separation. Detection was accomplished using a PE Sciex 365 triple quadrupole mass 
spectrometer modified with an Ionics EP10+ source.  Samples were reconstituted with 
the addition of 48 uL of 10 mM sodium phosphate buffer (pH 7.0) followed by 2 µL of 2-
vinylpyridine, and after a 30-minute room temperature incubation, 50 µL of 20 mM 
ammonium formate buffer pH 9.2 containing 7.5 mM N-butyl amine was added.  After 





Phenomenex (Torrance, CA) Gemini-NX C18 (150x3mm; 3 um particle size, 110A pore 
size) fitted with a Phenomenex security guard precolumn.  Data were recorded using 
Analyst 1.4.2 software with final peak heights recorded in Excel.  Data were normalized 
to weight and internal standard. 
Statistics 
Statistics were done using JMP pro statistical package using ANOVA with a 
Tukey-Kramer post hoc analysis to determine differences between groups. Results are 
presented as the mean ± the standard error of the mean.  
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Table 4.1 Physiologic factors of metabolism and iron.   






















Glucagon (pg/mL) 67.16 ± 5.51 60.43 ± 5.49 
78.07 ± 
8.743 
Body weight (g) 
29.89 ± 
0.27*** 28.09 ± 0.25 
28.65 ± 
0.176 
Total liver iron (ppm/mg 




Body weight is measured as n=72 per group. Iron was measured by ICP-OES, Optima 3100XL; PerkinElmer MS n=12 per group,  
ZT10. *p˂.05, **p˂.01, and ***p˂.001.  Hemoglobin and hematocrit measured by vetscan Hm5 n=6, ZT10.  Insulin and glucagon 















Figure 4.1 Dietary iron decreases parameters of glucose homeostasis and 
gluconeogenic transcription. A) ad libitum PTT at ZT12 and the B) AUCg (n=12-16) 
C) Liver PEPCK (n=6) and D) G6Pase mRNA as determined by RT-PCR normalized to 
cyclophilin and RPL13, which did not display circadian variation (n=6). *p˂.05, **p˂.01, 



















Figure 4.2 Dietary iron affects the formation of the Rev-Erbα repressor complex 
and its activity. A) Western blot of Rev-erbα IP extracts blotted for NCOR and Rev-
Erbα at ZT14 and B) quantification of these blots (n=6). C) ChIP of NCOR to the 
PEPCK (n=4) and D) G6Pase promoter determined by RT-PCR normalized to input at 















Figure 4.3 Hepatic heme synthesis and steady-state levels are altered with dietary 
iron. A) Total heme levels as measured by HPLC at ) ZT12 (n=6). B) Heme b levels as 
measured by hemochromagen pyridine assay at ZT12 (n=12). C)  ALAS1 transcripts 
determined by RT-PCR normalized to cyclophilin and RPL13 (n=6). *p˂.05, **p˂.01, 







Figure 4.4 Drug induced increase or decrease of heme levels ablates variations in 
heme, Rev-Erbα/NCOR complex formation, and gluconeogenesis observed between 
the various diets. A) Heme levels as measured by HPLC with ALA treatment and 
control (n=6-12) B) AUCg from ZT12 PTT (n=6) C) PEPCK (n=9), and D) G6pase 
mRNA transcripts in ALA treated and control mice normalized to RPL13 and 
cyclophilin(n=9). E) Western blot of Rev-Erbα IP extracts blotted for NCOR and Rev-
Erbα and F) quantification of the density of the NCOR blot normalized to the Rev-Erbα 
density. G) Heme levels as measured by HPLC with INH treated and control mice (n=3). 
H) AUCg for ZT12 PTT (n=5-8) I) PEPCK (n=5-8) and J) G6Pase transcript levels as 
measured by RT PCR normalized to RPL13 and cyclophilin in INH treated and control 
(n=5-8). K) Quantified density of NCOR bands normalized to Rev-Erbα density for L) 
Western blot for Rev-Erbα/NCOR coIP extracts blotted for Rev-Erbαand NCOR (n=3). 






Figure 4.5 Treatment of HepG2 cells with FAC, ALA, or INH recapitulates mouse 
results. A) PEPCK (n=12-24) and B) G6Pase transcript levels as measured by RT PCR 
for control and FAC cells with no drug treatment, ALA, or INH treated (n=12-24). C) 
Western blot of Rev-Erbα IP cell extract blotted for NCOR and Rev-Erbα and D) 
quantification of the density of the NCOR band as normalized to Rev-Erbα (n=3). 















Figure 4.6 Increased dietary iron increases PGC-1α and knockdown of PGC-1α 
abrogates differences between iron treated and nontreated HepG2 cells. A) PGC-1α 
mRNA as measured by RT PCR (n=6). B) Western blot of liver extracts blotted for PGC-
1α at ZT10 and C) Density of PGC-1α band normalized to β actin (n=6). D) Verification 
of PGC-1α KD by RT PCR (n=6) and E) PEPCK,(n=6) F) G6pase (n=6), and G) 















Figure 4.7 Dietary iron alters hepatocyte oxidant signaling and antioxidant 
treatment ablates differences in PGC-1α and gluconeogenic transcripts. A) GC 
MS/MS measurement of GSH (n=6) and B) NADPH/NADP+ in freeze clamped liver of 
mice on iron diets at various harvest times (n=6). C) Transcript levels of PGC-1α (n=3-
6), D) PEPCK (n=3-6), E) G6Pase (n=3-6), and F) ALAS1 in NAC treated and control 
mice (n=3-6). G) GC MS/MS measurement of GSH (n=3-6) and H) NADPH/NADP+ in 











4.S.1 Parameters of circadian glucose and feeding in C57BL/6J male mice fed LN, 
HN, and H diets. A) Fasting glucose levels obtained after 6 hour fast throughout the dark 
and light phase (n=10-16, *p=.0428, LN vs H p=.1405, HN vs H p=.0449) B) Area under 
the glucose curve (AUCg) for GTTs performed at various time points after a 6 hour fast 
(n=10-16, p) C) Feeding behavior as measured by electronic scale in the Comprehensive 








4.S.2 Rev-Erbα protein at ZT14 in the liver of C57BL/6J mice. A) Rev-Erb alpha blot 













4.S.3 ZT0 heme and circadian HO-1 in livers of male C57BL/6J mice. 3A) ZT0 
HPLC heme (p=.3236) B) ZT0 Hemochromogen pyridine heme b (p=.6361) C) HO-1 
transcript levels as normalized by RPL13 and cyclophilin B (ZT10 p=.0289, LN vs HN 
p=.3219, LN vs H p=.2193, HN vs H p=.0137; ZT14 p=.0018, LN vs HN p=.00237, LN 
vs H p=.0021, HN vs H p=.537; ZT18 p˂.0001, LN vs HN p=.0031, LN vs H p=.0002, 








In the US alone, approximately 14% of the adult population has diabetes (both 
diagnosed and undiagnosed) and current models predict that this incidence will rise to 25 
or 28% of the population developing diabetes by 2050 (Boyle et al., 2010). Results from 
other projections in individuals younger than 20 are especially startling and suggest that 
diabetes incidence may double by the year 2050 (Imperatore et al., 2012). With the 
continued rapid increase in this disease, it is important to explore the multifaceted causes 
associated with its rise. In this thesis, we have explored the impact of dietary iron on 
glucose homeostasis, specifically through its regulation of gluconeogenesis by increasing 
AMPK and Rev-Erbα activity. We showed that iron affects both of these pathways 
through either oxidative stress or oxidative signaling, and NAC treatment of mice 
abolished differences between the various iron diets.  
In previous reports, we demonstrated that AMPK phosphorylation is increased 
in the skeletal muscle in hepcidin knockout mice (Hfe-/-), a mouse model of the iron 
overload disorder hemochromatosis. The increase in AMPK activity seen in these mice 
correlates with increased removal of [1,2-13C2]D-glucose from the circulation, elevated 





the skeletal muscle (Huang et al., 2007). These differences may be due to the direct 
effects of iron on AMPK, or could result from the disease pathology of hemochromatosis. 
 In this thesis, we show increased AMPK phosphorylation in both skeletal 
muscle and liver with high dietary iron. In the liver, this increase in phosphorylated 
AMPK decreased hepatic gluconeogenesis by 13%, as shown by assessing the turnover 
of intraperitoneally injected  [U-13C6]-D-glucose.  We went on to show that iron increases 
AMPK activity through altering the acetylation of its regulatory kinase LKB1. 
Deacetylation of LKB1 has been shown to shift its cellular localization from the nucleus 
to the cytosol where it can phosphorylate AMPK. One of the major deacetylases of LKB1 
is Sirt1 (Lan et al.,2008). We showed that treatment of cells with Sirtuin inhibitors 
nicotinamide or splitomicin abrogates the increased AMPK phosphorylation with iron 
treatment (Huang et al., 2013). Sirt1 activity is known to respond to the oxidative state of 
the cell, and through NAC treatment of mice, we observed that the effects of iron on 
AMPK and AUCg of GTT were ameliorated. These results will likely impact other 
pathways, including circadian rhythms which are shown to regulate and be regulated by 
Sirt1. It will also be important to assess the effects of iron on other metabolic diseases 
including cancer, since we saw differences in both the acetylated and total levels of p53, 
a known tumor suppressor. 
We also found that variations in the oxidative state of the cell created by altering 
dietary iron were able to affect the circadian rhythm of the liver by increasing heme 
levels to affect Rev-Erbα/NCOR complex formation. Redox cofactors such as GSH and 
NADPH cycle and vary in an iron dependent manner (Figure 4.7 A and B).  These 





ZT10, which increase with dietary iron (Figure 4.6 A), and were ablated by treatment 
with the antioxidant NAC (Figure 4.7C). PGC-1α is known to regulate heme synthesis 
through transcriptional regulation of ALAS-1 (Handschin et al., 2005). As iron increased, 
we observed a graded increase in peak transcripts of ALAS-1 and heme levels at ZT12 
(Figure 4.3A-C). Heme is known to regulate the negative arm of the circadian regulon 
and is necessary for Rev-Erbα/NCOR complex formation, which inhibits the circadian 
factors Bmal1 and Clock as well as the gluconeogenic transcripts PEPCK and G6Pase 
(Yin et al., 2007). We observed there was higher Rev-Erbα/NCOR complex formation in 
H-fed mice when compared to the HN- and LN- fed mice (Figure 4.2 A and B). The 
changes in Rev-Erbα/NCOR complex correlated to an expected decrease in 
gluconeogenesis (Figure 4.1 A-D). Differences between the iron diets of complex 
formation and gluconeogenesis were heme dependent and treatment with drugs that 
increase (ALA) or inhibit (INH) heme synthesis ablated observed differences (Figure 
4.4).  
PGC-1α is a transcriptional coactivator that is known to be involved in a number 
of diverse metabolic pathways, including mitochondrial biogenesis, adaptive 
thermogenesis, and metabolism of both glucose and lipids (Liang and Ward, 2006). 
Upregulation of PGC-1α in the liver in response to increased dietary iron is a novel 
finding, and given its broad activation of metabolic pathways, other tissue depots should 
be assessed for altered expression in response to iron.  PGC-1α is also a known regulator 
of gluconeogenesis and is known to coactivate hepatic nuclear factor-4α (Hnf4α), 
glucocorticoid receptor (GR), and forkhead box1 (FOXO1) to increase transcription of 





observation that PGC-1α increase in H-fed mice, while PEPCK and G6Pase transcripts 
are decreased could be due to multiple promoter inputs from both AMPK and Rev-
Erbα/NCOR, or differences in PGC-1α binding partners.  Iron has never been reported to 
affect Hnf4α or GR; however, in previous studies, we have shown decreased acetylation 
of FOXO-1 with iron treatment. Typically, deactylation is associated with activation, but 
much like FOXO-1 control of adiponectin, deacetylation can also increase FOXO-1 
promoter coccupancy of the PPRE with PPARγ. This cooccupancy of FOXO-1 at the 
PPRE is inhibitory and may override the PGC-1α coactivation (Fan et al., 2009; 
Gabrielsen et al., 2012).  
The results presented in this dissertation confirm that heme is limiting for Rev-
Erbα/NCOR complex formation, although there is evidence that other factors are 
involved in the regulation of this complex, including the binding of NO, and the 
oxidation of thiol groups in the heme binding pocket (Cáceres et al., 2011; Shimizu, 
2012). Heme synthesis is highly regulated both at the level of anabolism and catabolism. 
ALAS-1 is transcriptionally inhibited by heme, and the enzyme that breaks down heme, 
heme oxygenase 1 (HO1), is transcriptionally upregulated by heme and by oxidative 
stress (Cable et al., 2000). We observe heme levels are highest in the H-fed mice at 
ZT12, before the start of the active period, while they are lowest in the H-fed mice at ZT0 
as the mice become inert. We also see that although ALAS-1 transcription is highest in 
H-fed mice at the peak at ZT10, H-fed mice have lower ALAS-1 transcript levels at other 
times, and increased HO-1 at ZT18. This temporal increase of heme synthesis directly 
before it is needed in pathways such as increased respiration, toxicity response, and 





orchestration of utilization and availability. It also suggests that upregulation of HO1 and 
downregulation of ALAS1 by heme, may not only be a mechanism to prevent the buildup 
of heme, which can be toxic in large quantities, but may also be a part of another 
regulatory loop that alters the circadian clock through regulation of heme to function in 
the daily rhythm of cellular metabolism.  
Future directions 
The decrease in gluconeogenesis that we observed in high iron diet is 
complicated by the understanding that iron in both pathologic and nonpathologic levels is 
associated with diabetes (Simcox and McClain, 2013). This may suggest that it may take 
multiple adverse conditions (i.e., genetic predisposition, obesity, dietary factors) to enter 
into a diabetic state. This multiple hit model is seen in diabetes associated with 
hemochromatosis. Patients with hemochromatosis actually have improved insulin 
sensitivity, and only begin to suffer from diabetes when their system is further stressed 
from weight gain, which leaves the insulin production insufficient for their mass 
(Cooksey et al., 2004). Although the mice on high iron diet have lower gluconeogenesis, 
they have decreased adiponectin levels and may require a second stress such as obesity, 
or aberrant feeding patterns to develop diabetes (Gabrielsen et al., 2012). Past studies 
performed in our laboratory have shown that restricting the food availability of mice to 8 
hours from ZT3-ZT10 for 1 week shifted their liver clock and the mice had a fasting 
glucose greater than 160, while a fasting glucose greater than 125 is symptomatic of 
diabetes (data not shown). In the future, it may be of interest to repeat the restriction 
feeding studies in mice on various iron diets to ascertain if the observed abnormal 





The data presented herein show that dietary iron is able to regulate the core 
molecular clock by altering temporal heme availability to change Rev-Erbα and NCOR 
binding. We have also generated data that show a correlation between high dietary iron 
and increased transcript levels of other clock components, including Clock, Bmal1, Per2, 
and Rev-Erbα (Figure 5.1A-D). These results could indicate that iron is limiting for 
absolute peak transcription or could suggest that iron is important in temporally 
regulating liver clock transcripts. Distinguishing between these two possibilities is 
complicated because of the 4- hour time period between harvests, which make it difficult 
to ascertain if these peak values are indeed the true peak for each of the diets or if they 
are instead the highest observed peak. In the future, to answer this question, it will be 
important to utilize an in vivo monitoring system such as the mPer2Luciferase mouse,  a 
knockin model expressing a luciferase reporter behind the Per2 promoter. Another 
question that these results raise is whether iron is feeding into this regulatory loop 
through the Rev-Erbα/NCOR complex alone, or if it could function through other 
mechanisms, including AMPK, oxidant signaling, or hypoxia, which are all shown to be 
altered in dietary iron and affect circadian rhythm.  
Another persisting question is the effects that dietary iron may have on body 
clocks other than the liver, including the central clock in the hypothalamus. At ZT10, we 
observed that the total iron levels increased with dietary iron in the liver (Table 4.1); 
however, in the hypothalamus, we observed decreased total iron stores with increased 
dietary iron (Figure 5.2 A). The SCN is known to regulate feeding behavior, activity, and 
body temperature. Through monitoring of body temperature with the VitaView Data 





circadian oscillations in body temperature. We observed that the L-fed mice varied from 
peak to trough by 1.44±0.04˚C while the HN group only varied by 1.26±.04˚C (Figure 
5.2B). These differences could be due to either differences in heat capacity of the LN- fed 
mice (white or brown adipose depots) or due to differences in SCN regulation. In a recent 
publication, Chen et al. (2013) showed that iron was necessary to set the rhythm of the 
core molecular clock. Plants grown in iron deficient soil had lower peak heights in 
circadian factors, and when moved to a constant dark condition, the transcript peaks 
began to shift from the iron sufficient controls. To elucidate if dietary iron in mice 
functions to maintain circadian timing of the SCN similar to its function in Arabidopsis, 
we will keep the mice in constant dim light conditions while monitoring their body 
temperatures. After the light manipulation, we will also perform a cold tolerance test to 
assess if there are differences in thermogenesis between the diets.  
Final summary 
In summary, our results show that dietary iron is able to regulate gluconeogenesis 
through its input into two central metabolic pathways: AMPK and circadian rhythms. The 
modulation of these pathways by iron is through oxidative signaling, and suggests that 
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Figure 5.1 Transcripts of molecular clock components from the liver of 
C57BL/6J mice.  A) Bmal1, B) Clock, C) Per2, and D)Rev-Erbα transcripts as 
measured by RT-PCR (n=6 per diet per timepoint, *p˂.05, **p˂.01, and 






Figure 5.2 The effects of dietary iron on hypothalamic iron and body 
temperature. A) Total iron stores measured by ICP-OES, Optima 3100XL; 
PerkinElmer (p value calculated by ANOVA, L vs HN p=.0001, L vs H p˂.0001, 
HN vs H p=.0346). B) Body temperature as measured by VitaView Data 
Acquisition System (Respironics) analyzed by jmp pro. 
